|
|
Post by patten1962 on Sept 29, 2016 10:48:56 GMT -5
Thank you. My friend said the reports can be estimated. Her company uses IMS. I am just sharing what was told by people in the industry. Just makes no sense that 50 sales reps in almost 3 months only have 7 or so new scripts. Any thoughts? I always enjoy your posts. Thank you. I'm not sure how you come up with 7 new scripts? Each tally of NRx is a new number of scripts. They are capturing 114 per week. Sorry, hyperbole... |
|
|
|
Post by epc1355 on Sept 29, 2016 10:49:21 GMT -5
Does anyone know exactly how they come up with the script numbers? I was under the impression it was a just a sampling and then an estimate. How accurate are these numbers?
|
|
|
|
Post by patten1962 on Sept 29, 2016 10:58:05 GMT -5
Does anyone know exactly how they come up with the script numbers? I was under the impression it was a just a sampling and then an estimate. How accurate are these numbers? Eric, I believe my friends. And if the script numbers are way up each or any of the next 4 Fridays, maybe what they said is true. |
|
|
|
Post by sweedee79 on Sept 29, 2016 11:30:05 GMT -5
here is our answer to scripts.
sweedee dad.
demand being resisted by physicians.
Was sweedee's dad physician also resisting the office work involved in the script?
That physician could see the difference in A1c and weight.
Any chance the guidelines change and three medications would not have to be failed before insulin initiated type 2?
Targets have to be Type 1. Freedom. How many type one's waiting for scripts with insurance help from Mannkind? Stay tuned. Freedom.
I wonder how Jay S could illustrate the dreamboat as freedom. You are right Peppy... every single doc my dad has had during all of this has complained and wants nothing to do with insurance problems or writing letters to insurance companies.. one of his docs flat out told him " I want nothing to do with it, I'm too busy already, I don't have time for it" ...
While looking for insurance for my dad Ive noticed that all insulin including Novolog is now tier 3 or 4 on part D plans.. what is going on?? These poor seniors were promised health care and insurance in their old age... the whole system is so complicated you need to be a lawyer to figure it all out.. My mom has dementia and my dad doesn't understand it all either ... so now I'm studying Medicare parts A, B and D .. and whatever other freaking parts there are... and also insurance plans which in themselves are complicated... why cant things just be simple??? What would be wrong with simple???
Anyway, it isn't just Afrezza that goes up against stuff like this... pretty much every single new diabetes drug isn't covered very well.. and is resisted by physicians... for the most part Medicare itself doesn't cover any drugs... patients now have to buy their own insurance plans for that... I'm thinking that until I can get better coverage for my dad on Afrezza.. we may have to try Apidra.. its better than both Novolog and Humalog .. will see.. but even Apidra isn't covered very well and not on many formularies either and it has been around for a while..
I wonder what insurance coverage is for people who aren't on Medicare... I sure hope its way better than this.. In any case until we are ready for TV ads the increase in scripts will climb slow and steady .. the reps are setting the stage and that will not result in an explosion of scripts.. so we have to keep our expectations in check..
The only thing that is going to get these docs to change their ways is patient demand...
|
|
|
|
Post by kball on Sept 29, 2016 11:38:03 GMT -5
here is our answer to scripts.
sweedee dad.
demand being resisted by physicians.
Was sweedee's dad physician also resisting the office work involved in the script?
That physician could see the difference in A1c and weight.
Any chance the guidelines change and three medications would not have to be failed before insulin initiated type 2?
Targets have to be Type 1. Freedom. How many type one's waiting for scripts with insurance help from Mannkind? Stay tuned. Freedom.
I wonder how Jay S could illustrate the dreamboat as freedom. You are right Peppy... every single doc my dad has had during all of this has complained and wants nothing to do with insurance problems or writing letters to insurance companies.. one of his docs flat out told him " I want nothing to do with it, I'm too busy already, I don't have time for it" ...
While looking for insurance for my dad Ive noticed that all insulin including Novolog is now tier 3 or 4 on part D plans.. what is going on?? These poor seniors were promised health care and insurance in their old age... the whole system is so complicated you need to be a lawyer to figure it all out.. My mom has dementia and my dad doesn't understand it all either ... so now I'm studying Medicare parts A, B and D .. and whatever other freaking parts there are... and also insurance plans which in themselves are complicated... why cant things just be simple??? What would be wrong with simple???
Anyway, it isn't just Afrezza that goes up against stuff like this... pretty much every single new diabetes drug isn't covered very well.. and is resisted by physicians... for the most part Medicare itself doesn't cover any drugs... patients now have to buy their own insurance plans for that... I'm thinking that until I can get better coverage for my dad on Afrezza.. we may have to try Apidra.. its better than both Novolog and Humalog .. will see.. but even Apidra isn't covered very well and not on many formularies either and it has been around for a while..
I wonder what insurance coverage is for people who aren't on Medicare... I sure hope its way better than this.. In any case until we are ready for TV ads the increase in scripts will climb slow and steady .. the reps are setting the stage and that will not result in an explosion of scripts.. so we have to keep our expectations in check..
The only thing that is going to get these docs to change their ways is patient demand...
Avatar frown understandable. So frustrating just to read, let alone try and help a loved one through the maze, let alone being the elderly person w the disease and distress. *sigh* |
|
|
|
Post by cjm18 on Sept 29, 2016 13:36:12 GMT -5
Does anyone know exactly how they come up with the script numbers? I was under the impression it was a just a sampling and then an estimate. How accurate are these numbers? Eric, I believe my friends. And if the script numbers are way up each or any of the next 4 Fridays, maybe what they said is true. Let's assume there are monthly delays in script reporting like your friends say. . Wouldn't those delays impact every week of the weekly script data in a similar manner? Why expect scripts to improve now unless we have reason to believe there were more "reporting delays" at a certain time? |
|
|
|
Post by peppy on Sept 29, 2016 13:54:54 GMT -5
We expect scripts to improve because afrezza technosphere insulin, as seen on continuous glucose monitors, offers enhanced glycemic control post meal time by stimulating the liver to stop glucose production the first phase insulin reaction, that rapid acting analogues do not provide, and then lowering blood glucose levels as it's dimers work.
This is why we expect scripts to rise. It is a superior insulin.
"Onset of activity for TI occurred ca. 25-35 minutes earlier than for
Lispro. TI duration of action is about 2 hours shorter than an equivalent
dose of Lispro." "Each 4 unit Afrezza cartridge provides approximately the same
insulin exposure as 3.1 U Lispro"
We expect scripts to increase, because we are not blind, we can see. per continuous glucose monitors.
(Did Mike H say for his correction thesis, 4 unit will decrease his blood glucose 30,g/dl in 90 mins?)
www.mannkindcorp.com/Collateral/Documents/English-US/Baughman%20poster%20100-LB%20FINAL%20X2.pdf
Added. In all fairness, our smartest brightest physicians can see.
|
|
|
|
Post by cjm18 on Sept 29, 2016 14:00:39 GMT -5
We expect scripts to improve because afrezza technosphere insulin, as seen on continuous glucose monitors, offers enhanced glycemic control post meal time by stimulating the liver to stop glucose production the first phase insulin reaction, that rapid acting analogues do not provide, and then lowering blood glucose levels as it's dimers work.
This is why we expect scripts to rise. It is a superior insulin.
"Onset of activity for TI occurred ca. 25-35 minutes earlier than for
Lispro. TI duration of action is about 2 hours shorter than an equivalent
dose of Lispro." "Each 4 unit Afrezza cartridge provides approximately the same
insulin exposure as 3.1 U Lispro"
We expect scripts to increase, because we are not blind, we can see. per continuous glucose monitors.
(Did Mike H say for his correction thesis, 4 unit will decrease is blood glucose 30,g/dl in 90 mins?)
www.mannkindcorp.com/Collateral/Documents/English-US/Baughman%20poster%20100-LB%20FINAL%20X2.pdf
Hopefully scripts do jump but it won't be from any reporting delay. |
|
|
|
Post by patten1962 on Sept 29, 2016 14:19:44 GMT -5
We expect scripts to improve because afrezza technosphere insulin, as seen on continuous glucose monitors, offers enhanced glycemic control post meal time by stimulating the liver to stop glucose production the first phase insulin reaction, that rapid acting analogues do not provide, and then lowering blood glucose levels as it's dimers work.
This is why we expect scripts to rise. It is a superior insulin.
"Onset of activity for TI occurred ca. 25-35 minutes earlier than for
Lispro. TI duration of action is about 2 hours shorter than an equivalent
dose of Lispro." "Each 4 unit Afrezza cartridge provides approximately the same
insulin exposure as 3.1 U Lispro"
We expect scripts to increase, because we are not blind, we can see. per continuous glucose monitors.
(Did Mike H say for his correction thesis, 4 unit will decrease is blood glucose 30,g/dl in 90 mins?)
www.mannkindcorp.com/Collateral/Documents/English-US/Baughman%20poster%20100-LB%20FINAL%20X2.pdf
Hopefully scripts do jump but it won't be from any reporting delay. Well I am confused. My friends have been pharmaceutical reps for 20+ years. Not sure why they would both be incorrect? Is anyone here in pharmaceutical sales? Not being sarcastic, really just wondering? |
|
|
|
Post by cjm18 on Sept 29, 2016 14:55:58 GMT -5
Read my post prior to Peppys post. Im not saying there aren't any month delays or that your friends are wrong. I don't know.
Im saying the delays don't impact the trend of the data. They impact the raw prescription counts every week in the SAME manner. So bump up every week by 5% if you want. The trend is still the same.
|
|
|
|
Post by cjm18 on Sept 29, 2016 14:58:23 GMT -5
Why would "delays" impact tomorrow's scripts more than last week? Or the week before? Or the week before that.
|
|
Deleted
Deleted Member
Posts: 0
|
Post by Deleted on Sept 29, 2016 16:13:03 GMT -5
why would there be a 3 month lag, are the messengers walking!?
|
|
Deleted
Deleted Member
Posts: 0
|
Post by Deleted on Sept 29, 2016 16:52:04 GMT -5
Does anyone know exactly how they come up with the script numbers? I was under the impression it was a just a sampling and then an estimate. How accurate are these numbers? The subject of script counting/reporting was a hot topic in early 2015 and I recall posting links explaining the basics of what symphony and ims does but couldn't locate it. In any event, harry has a good summary here: mnkd.proboards.com/thread/2013/ims-reports-scriptsAnd there's another explanation located here: seekingalpha.com/instablog/175233-spencer-osborne/2907043-ims-health-vs-symphony-health-counting-scriptsIf memory serves, ims and symphony collect data from some of the big prescription houses and then do some magical math to arrive at an estimate for those that won't report data. One the one hand you could say then the data is faulty. On the other, it's their business to get it as close as they can since they sell that data. If it were bad data companies would eventually stop using the service, or so one would think. But, imo and from my point of view, I look at what the script counts are telling us week to week and then adjust when the quarterlies come out using the reported rev numbers for the quarter. It's hardly perfect but if there were a lot of unreported scripts, at some point that discrepancy will show in the quarterly rev numbers. |
|
|
|
Post by audiomr on Sept 30, 2016 0:00:47 GMT -5
Does anyone know exactly how they come up with the script numbers? I was under the impression it was a just a sampling and then an estimate. How accurate are these numbers? The subject of script counting/reporting was a hot topic in early 2015 and I recall posting links explaining the basics of what symphony and ims does but couldn't locate it. In any event, harry has a good summary here: mnkd.proboards.com/thread/2013/ims-reports-scriptsAnd there's another explanation located here: seekingalpha.com/instablog/175233-spencer-osborne/2907043-ims-health-vs-symphony-health-counting-scriptsIf memory serves, ims and symphony collect data from some of the big prescription houses and then do some magical math to arrive at an estimate for those that won't report data. One the one hand you could say then the data is faulty. On the other, it's their business to get it as close as they can since they sell that data. If it were bad data companies would eventually stop using the service, or so one would think. But, imo and from my point of view, I look at what the script counts are telling us week to week and then adjust when the quarterlies come out using the reported rev numbers for the quarter. It's hardly perfect but if there were a lot of unreported scripts, at some point that discrepancy will show in the quarterly rev numbers. If that is how it works, the reports would likely be very noisy for drugs with low scrip counts (such as Afrezza currently). It's hard to do a good statistical approximation from a small sample. |
|
